Prof. John Pasi, Consultant Haematologist

Prof. John Pasi MB ChB PhD FRCP FRCPath

Consultant Haematologist

MB ChB PhD FRCP FRCPath

Areas of expertise

  • Haemostasis
  • Pulmonary thrombo-embolism
  • Thrombosis
  • Bleeding disorders
  • Haemophilia

Recommendations for Prof. Pasi

These recommendations are for information purposes only. Doctors providing recommendations do so in good faith and are not responsible for clinical outcomes.

Recommended by:

  • byDr Paul Glynne, General (Internal) Medicine

    Professor John Pasi is the most knowledgeable thrombosis doctor in London - you cannot get a better opinion for patients diagnosed with deep vein thrombosis or pulmonary embolus. Very good advice provided about anti-coagulant therapy.

  • byDr Syed Ahsan, Cardiologist

    John Pasi is an excellent haematologist. We’ve had mutual patients. He is well-known and has lots of experience.

  • byMr Nima Heidari, Foot and Ankle Surgeon

    Trusted colleague and would be happy to refer a member of family to him.

  • byDr Paul Glynne, General (Internal) Medicine

    Professor John Pasi is the most knowledgeable thrombosis doctor in London - you cannot get a better opinion for patients diagnosed with deep vein thrombosis or pulmonary embolus. Very good advice provided about anti-coagulant therapy.

  • byDr Syed Ahsan, Cardiologist

    John Pasi is an excellent haematologist. We’ve had mutual patients. He is well-known and has lots of experience.

  • byMr Nima Heidari, Foot and Ankle Surgeon

    Trusted colleague and would be happy to refer a member of family to him.

  • Address

    About Prof. John Pasi

    GMC number: 2807876

    Year qualified: 1983

    Place of primary qualification: University of Birmingham

    Areas of expertise

    • Haemostasis
    • Pulmonary thrombo-embolism
    • Thrombosis
    • Bleeding disorders
    • Thrombotic disorders

    Professional memberships

    Royal College of Pathologists
    General Medical Council

    Articles by Prof. John Pasi

    Perioperative management of patients with hemophilia receiving fitusiran, an investigational rnai therapeutic targeting antithrombin for the treatment of hemophilia

    Recombinant factor viii fc fusion protein for the treatment of severe haemophilia a: final results from the aspire extension study

    The impact of factor infusion frequency on health-related quality of life in people with haemophilia

    De novo truncating mutations in wasf1 cause intellectual disability with seizures

    Targeting of antithrombin in hemophilia a or b with rnai therapy